1μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | GPRchr2, WI31133 |
| Accession | O95800 |
| Concentration | 1mg/ml by Nanodrop |
| Amino Acid Sequence | Gly31-Val235 & Ser307-Leu396 with Strep and His tag at the C-terminus |
| Expression System | Baculovirus-InsectCells |
| Molecular Weight | 43-55kDa (Reducing) |
| Purity | >95% by SDS-PAGE |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tags & Cleavage sites | 3C, Tev, Sortase A |
| Tag | His Tag, Strep Tag |
| Physical Appearance | Liquid with detergent |
| Storage Buffer | 20 mM Tris,pH 7 .5,150 mM NaCl,0 .00075% LMNG,0 .0001% CHS,0 .00025% GDN,1x Protease Inhibitor Cocktail,100μM TCEP |
| Stability & Storage | ·6 months from date of receipt, -60 to -80 °C as supplied. |
| Reference | 1. Lv Z, He Y, Xiang Y, et al. Cryo-EM complex structure of active GPR75 with a nanobody[J]. bioRxiv, 2022: 2022.08. 18.503988. |
Background
The rising prevalence of obesity and its associated co-morbidities has become a global healthcare concern. Treating obesity clinically remains a significant challenge. GPR75, a member of the G protein-coupled receptor (GPCR) family, has emerged as a novel target for managing obesity and related metabolic disorders. Studies have demonstrated that the GPR75 signaling pathway can be inhibited by small molecules and antibodies, offering a potential therapeutic strategy for obesity. The GPR75 product may enhance the development of in silico drug discovery efforts targeting obesity and its associated co-morbidities.
Picture
Picture
SDS-PAGE
